May 2014 – QPS360 Newsletter – 8th Edition
Corporate
Dr. Caroline Lee Recognized as ASCPT Member of the Month  
   
QPS Austria Runs the Graz Business Marathon  
Neuropharmacology
Dinaciclib, a Potent Cyclin-Dependent Kinase Inhibitor, and its Novel Function in Neuronal Development  
   
Tau Phosphorylation - A Hot Topic in CNS Research  
   
Arterial Diameter Progressively increases in Mutant AD Mice - a Comparative Study to Human AD Cases  
DMPK
Metabolite Profiling Using Human Hepatocyte Co-cultures and UHPLC-Q-TOF-MS with Data Independent MS/MS  
   
Eric Solon Co-presents Poster at AACR (American Association for Cancer Research) Annual Meeting showing the Tissue Disposition Profile of a 2nd Generation Hypomethylating Agent  
   
Metabolic Stability Assay Using Human Hepatocyte Co-cultures and Integrated Qualitative/Quantitative High Resolution Mass Spectrometry  
   
In Vitro Species Comparison using Long-term Hepatocyte Co-Culture Models and Highly Sensitive UHPLC-Q-TOF-MS with SWATH Analysis  
   
Eric Solon, QPS’ Fellow of Autoradiography & Radiation Safety Officer Co-authors Book Chapter on Quantitative Pharmaco-Imaging Using Autoradiographic Techniques  
Bioanalysis
Dwell Time, a Critical Factor on Precision in N-in-One Assays Utilizing UPLC-MS/MS  
   
Development and Validation of an Ultra-Sensitive UPLC-MS/MS Method for the Determination of Naloxone in Human Plasma  
   
A Simple, Reliable and Rapid LC-MS/MS Method for Simultaneous Determination of Carbamazepine and Carbamazepine-10,11-epoxide in Human Plasma  
   
Overcoming Chiral Method Development Challenges: UPLC-MS/MS Method Development for Determination of Dextroamphetamine and Levoamphetamine in Human Plasma after Chiral Derivatization  
Translational Medicine
Monique Putman, Manager Biochemistry & Immunology at QPS, on International Team of Experts Exploring the Impact of Immunogenicity on Pharmacokinetic (PK) Assessments – Resultant Recommendations for Bioanalytical Best Practices Captured in American Association of Pharmaceutical Scientists (AAPS) White Paper  
Early Stage Clinical
QPS Bio-Kinetic, Early Phase Clinical Trials: 20 Years of Experience Really Add Up  
   
QPS Netherlands, Early Phase Clinical Trials: 10 Years of Experience Really Add Up  
 
 
Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, topical transdermal delivery systems (TDDS) are designed to treat systemic medical conditions or localized joint or muscle conditions, using the skin as the route of drug delivery. Transdermal drug delivery offers important advantages over other routes of administration. It is particularly useful for circumventing liver first-pass metabolism, as an alternative to oral products, for non-invasive localized muscle and joint treatments, to improve and simplify patient compliance, and to allow for discontinuation of drug delivery by removing the patch in the event of adverse drug reactions. TDDS have become successful alternatives for delivering medications to young children, the elderly and the infirm.